The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001799:Blood Sedimentation; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy*; D003672:Defecation / Q000187:drug effects; D003864:Depression, Chemical; D005260:Female; D005334:Fever / Q000139:chemically induced; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000097:blood; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010919:Placebos; D012709:Serum Albumin / Q000378:metabolism; D013268:Stimulation, Chemical; D012460:Sulfasalazine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D006454:Hemoglobins; D010919:Placebos; D012709:Serum Albumin; D012460:Sulfasalazine; D007501:Iron